(Press-News.org) Fairfax, Va., April 6, 2015--Long-term analysis of Radiation Therapy Oncology Group (RTOG) 9903 demonstrates that the addition of erythropoietin (EPO) did not improve local-regional control for anemic patients with head and neck squamous cell carcinoma (HNSCCa) who receive radiation therapy or chemoradiation, according to a study published in the April 1, 2015 issue of the International Journal of Radiation Oncology * Biology * Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO). This study is a long-term analysis of RTOG 9903, originally published in 2007[1], to determine if there were additional failures, second primaries and/or toxicities at a longer follow-up of eight years.
RTOG 9903, an open-label, Phase 3 randomized trial, examined if the addition of EPO, which stimulates the body's bone marrow to increase red blood cell production to prevent and to treat anemia, to radiation therapy would improve disease control in anemic patients with HNSCCa. The study accrued 148 patients from June 2000 to November 19, 2003, and fifty-four cancer centers participated in the trial. Eligible patients had HNSCCa of the oral cavity, oropharynx, hypopharynx or larynx; had a Zubrod performance status of zero to two (the Zubrod score indicates a patient's health status from zero to four, with zero indicating a patient is "fully active, able to carry on all pre-disease activities without restriction" and four indicating a patient is "completely disabled, cannot carry on any self-care, totally confined to bed or chair"); and hemoglobin levels ?13.5 g/dL for males and ?12.5 g/dL for females. After enrollment in the study, four patients were considered ineligible, and three patients withdrew from the trial.
Of the 141 patients included in the study, 69 were randomized to receive radiation therapy or chemotherapy plus radiation, and 72 were randomized to receive radiation therapy or chemotherapy plus radiation with EPO. Patients randomized to receive EPO received the first dose seven to 10 days prior to beginning radiation therapy, and then received EPO in a weekly dose of 40,000 units throughout treatment, unless hemoglobin levels exceeded 16 g/dL for males or 14 g/dL for females. Patients whose hemoglobin levels did not increase ?1 g/dL after four doses of EPO received a dose increase to 60,000 units.
During treatment, patients were evaluated weekly for toxicities and review of their complete blood count. Follow-up was conducted at two and four weeks after treatment was completed, then every three months for the first two years post-treatment, every six months for the next three years and annually thereafter. For this long-term analysis, the median follow-up for surviving patients was 7.95 years (range 1.66 to 10.08 years) and 3.33 years for all patients (range 0.03 to 10.08 years).
This new analysis of RTOG 9903 found that at five-year follow-up, the local-regional failure rate was 39.4 percent for patients who received radiation therapy or chemoradiation without EPO and 46.2 percent for patients who received EPO (Hazard Ratio (HR) 1.27 on univariate analysis and 1.40 on multivariate analysis). The five-year local-regional progression-free survival rate was 37.6 percent for patients who did not receive EPO and 31.5 percent for patients who received EPO (HR 1.28 on univariate analysis and 1.39 on multivariate analysis). The five-year overall survival rate was 38.2 percent for patients who did not receive EPO and 36.9 percent for patients who received EPO (HR 1.13 on univariate analysis and 1.23 on multivariate analysis). The five-year distant metastases rate was 14.5 percent for patients who did not receive EPO and 15.6 percent for patients who received EPO (HR 1.03 on univariate analysis and 1.07 on multivariate analysis). The confidence interval for all measures was 95 percent. None of the differences were statistically significant; however, the HR in this long-term follow-up demonstrated improved outcomes for the patients who did not receive EPO.
"It is well-known that cancer patients with anemia (low hemoglobin) have lower cure rates than patients with normal hemoglobin levels. RTOG 9903 was aimed at improving the outcomes of anemic patients with head and neck squamous cell carcinoma by restoring their hemoglobin levels to normal," said George Shenouda, MD, lead author of the study and an associate professor of oncology and otolaryngology at McGill University Health Centre in Montreal. "The initial analysis of the results was unexpected and led to the study's early closure because of a possible detrimental effect of EPO. While EPO improved hemoglobin levels, the control rates were not similarly improved. This long-term analysis confirms that EPO is not the appropriate treatment option for our anemic HNSCCa cancer patients. It is important for us to be aware that EPO is a growth factor and as such, may stimulate the growth of cancer cells, resulting in decreased tumor control. Carefully designed clinical trials are required to address how to treat anemia in our cancer patients."
An accompanying editorial from Todd A. Aguilera, MD, PhD, and Amato J. Giaccia, PhD, also published in the April 1 issue of the Red Journal, examines the implications of the study and the need to address tumor hypoxia in future clinical trials.
INFORMATION:
For a copy of the study manuscript, contact ASTRO's Press Office at press@astro.org. For more information about the Red Journal, visit http://www.redjournal.org.
[1] Machtay M, Pajak T, Suntharalingam M, et al. Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: A randomized trial of the Radiation Therapy Oncology Group (RTOG 9903). Int J Rad Oncol Biol Phys 2007; 69: 1008-1017.
About ASTRO
ASTRO is the premier radiation oncology society in the world, with nearly 11,000 members who are physicians, nurses, biologists, physicists, radiation therapists, dosimetrists and other health care professionals that specialize in treating patients with radiation therapies. As the leading organization in radiation oncology, the Society is dedicated to improving patient care through professional education and training, support for clinical practice and health policy standards, advancement of science and research, and advocacy. ASTRO publishes two medical journals, International Journal of Radiation Oncology * Biology * Physics and Practical Radiation Oncology; developed and maintains an extensive patient website, http://www.rtanswers.org; and created the Radiation Oncology Institute, a non-profit foundation to support research and education efforts around the world that enhance and confirm the critical role of radiation therapy in improving cancer treatment. To learn more about ASTRO, visit http://www.astro.org.
WASHINGTON, April 6, 2015 -- The fantasy epic Game of Thrones is back this Sunday night, and it is sure to be chock full of intrigue, indiscretions and, of course, swords. The most sought-after blades in Westeros are made from Valyrian steel, forged using ancient magic. But could you make your own Valyrian steel sword using real-life chemistry? Reactions collaborated with cosplaying chemistry fanatic and material scientist Ryan Consell to see if we could blend metallurgy with Westerosi magic. Check out the video here: https://youtu.be/cHRcGoje4j4.
INFORMATION:
Subscribe ...
DURHAM, N.C. - Salt marshes at higher latitudes, such as those in densely populated coastal regions of New England and northern Europe, are more vulnerable to the effects of nutrient pollution, a new Duke University study finds.
"The heavy flow of nitrogen and phosphorus into these marshes from upstream cities and farms can trigger a chain reaction that can lead to intense overgrazing by marsh herbivores," said Brian R. Silliman, Rachel Carson Associate Professor of Marine Conservation Biology at Duke's Nicholas School of the Environment.
"Left unchecked, this overgrazing ...
People undergoing treatment for HIV-1 have an increased risk for earlier onset of age-related illnesses such as some cancers, renal and kidney disease, frailty, osteoporosis and neurocognitive disease. But is it because of the virus that causes AIDS or the treatment?
To answer that question, researchers at the UCLA AIDS Institute and Center for AIDS Research and the Multicenter AIDS Cohort Study investigated whether the virus induces age-associated epigenetic changes -- that is, changes to the DNA that in turn lead to changes in expression of gene levels without changing ...
A new blood test may more accurately identify blood signatures, or biomarkers, for Parkinson's disease (PD), according to a new study published in the journal Movement Disorders. The study, conducted by researchers at Mount Sinai and funded by the Michael J. Fox Foundation for Parkinson's Research, applies a new approach to looking for blood biomarkers for both patients with and without a known genetic risk factor for PD. This paper is the fourth in a series that report new computational techniques to improve the identification of reliable blood biomarkers.
While biomarkers--such ...
Forty percent of all malaria-caused deaths in sub-Saharan Africa occur in the Democratic Republic of Congo and Nigeria, according to the World Health Organization. The private sector "supply chain" manages 74% of the drug volume in Congo and 98% in Nigeria where malaria-stricken patients rely on "drug shops" and other for-profit retail outlets to get life-saving medicine.
New research forthcoming in Management Science determines that the "shelf life" of malaria-fighting drugs plays a significant role in how donors should subsidize the medicine in order to ensure better ...
A study published today on the safety of human breast milk bought over the Internet found that 10 percent of samples contained added cow's milk. The discovery that purchased samples of human milk may be purposely "topped off" with cow's milk or infant formula confirms a danger for the large number of babies receiving the purchased milk due to medical conditions. These babies are also vulnerable to the risk of infectious disease from bacterial and viral contamination of such milk, which was identified in a prior study by the same research team led by Nationwide Children's ...
ANN ARBOR, Mich. -- Two young men in their late teens sit in adjacent rooms of an inner-city emergency room. One is getting care for injuries he suffered in a fight, the other, for a sore throat. When the nurse tells each one he can go, both head back out to an environment rampant with violence, poverty and traumatic life experiences.
But, a new University of Michigan study finds, the one who had been in a fight will have a nearly 60 percent chance of becoming involved in a violent incident involving a firearm within the next two years. If he does, it'll probably happen ...
CAMBRIDGE, Mass. (April 3, 2015) - By modifying the CRISPR-Cas genome editing system, Whitehead Institute researchers are now able to manipulate Candida albicans' genome systematically--an approach that could help identify novel targets for therapies against this serious pathogen for which there are a limited number of anti-fungal agents.
"The ability to engineer Candida albicans with CRISPR technology has changed the playing field," says Whitehead Founding Member Gerald Fink, who is also a professor of biology at MIT. "We used to attack this human pathogen with our hands ...
A research team showed that a nanotherapeutic medicine can halt the growth of artery plaque cells resulting in the fast reduction of the inflammation that may cause a heart attack, according to a study led by researchers from Icahn School of Medicine at Mount Sinai and published April 3 in Science Advances.
"In just one week our novel cell proliferation-specific approach successfully suppressed atherosclerotic plaque growth and inflammation in mice engineered to mimic human vascular disease," says lead study author Jun Tang, MS, a PhD student at Icahn School of Medicine ...
A proposed pathway to construct quantum computers may be the outcome of research by a University of Oklahoma physics team that has created a new molecule based on the interaction between a highly-excited type of atom known as a Rydberg atom and a ground-state atom. A unique property of the molecule is the large permanent dipole moment, which reacts with an electric field much like a bar magnet reacts with a magnetic field.
"This is the largest electric dipole moment ever observed in a molecule," says James Shaffer, professor in the Homer L. Dodge Department of Physics ...
